BRI initiates Phase 2 clinical trial of Antineoplastons A10 and AS2-1 in DIPG patients

Burzynski Research Institute (BRI) has started patient enrolment for a Phase 2 study of Antineoplastons A10 and AS2-1 in patients below the age of 3 months with diffuse intrinsic brainstem glioma (DIPG) disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news